Nanomedicine-mediated cancer stem cell therapy

Biomaterials

Volumn 74, Issue , 2016, Pages 1-18

  Shen, Song ^a   Xia, Jin Xing ^a   Wang, Jun ^a,b  

^a UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^b UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

Author keywords

ATP binding cassette transporter; Cancer stem cells; CSC specific agents; Drug delivery; Drug resistant; Nanomedicine

Indexed keywords

BINS; CELLS; CYTOLOGY; DISEASES; DRUG DELIVERY; DRUG THERAPY; NUCLEIC ACIDS; STEM CELLS; TUMORS;

ATP BINDING CASSETTE TRANSPORTERS; CANCER STEM CELLS; CLINICAL APPLICATION; DRUG DELIVERY TECHNOLOGIES; DRUG-RESISTANT; MULTIDRUG RESISTANCE; SMALL-MOLECULE DRUGS; THERAPEUTIC STRATEGY;

MEDICAL NANOTECHNOLOGY;

ABC TRANSPORTER; ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; CELL SURFACE MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; NANOCARRIER; NANOPARTICLE; NUCLEIC ACID; TRANSFERRIN RECEPTOR;

AUTOPHAGY; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; CANCER THERAPY; CELL METABOLISM; CELL RENEWAL; CELL SURVIVAL; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EXTRAVASATION; DRUG SAFETY; DRUG TARGETING; GENOME; HUMAN; INTERNALIZATION; MULTIDRUG RESISTANCE; NANOMEDICINE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RNA EDITING; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; ANIMAL; DRUG EFFECTS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; HUMANS; NANOMEDICINE; NEOPLASTIC STEM CELLS;

EID: 84945161573     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.09.037     Document Type: Review

References (218)

1. Nowell P.C. The clonal evolution of tumor cell populations. Science 1976, 194:23-28.
2. Quintana E., Shackleton M., Foster H.R., Fullen D.R., Sabel M.S., Johnson T.M., et al. Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell 2010, 18:510-513.
3. Meacham C.E., Morrison S.J. Tumour heterogeneity and cancer cell plasticity. Nature 2013, 501:328-337.
4. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 1997, 3:730-737.
5. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
6. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:3983-3988.
7. Pece S., Tosoni D., Confalonieri S., Mazzarol G., Vecchi M., Ronzoni S., et al. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 2010, 140:62-73.
8. Singh S.K., Hawkins C., Clarke I.D., Squire J.A., Bayani J., Hide T., et al. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.
9. Eramo A., Lotti F., Sette G., Pilozzi E., Biffoni M., Di Virgilio A., et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 2008, 15:504-514.
10. O'Brien C.A., Pollett A., Gallinger S., Dick J.E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007, 445:106-110.
11. Ricci-Vitiani L., Lombardi D.G., Pilozzi E., Biffoni M., Todaro M., Peschle C., et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007, 445:111-115.
12. Diehn M., Clarke M.F. Cancer stem cells and radiotherapy: new insights into tumor radioresistance. J. Natl. Cancer Inst. 2006, 98:1755-1757.
13. Yang Z.F., Ho D.W., Ng M.N., Lau C.K., Yu W.C., Ngai P., et al. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell 2008, 13:153-166.
14. Li C., Heidt D.G., Dalerba P., Burant C.F., Zhang L., Adsay V., et al. Identification of pancreatic cancer stem cells. Cancer Res. 2007, 67:1030-1037.
15. Maenhaut C., Dumont J.E., Roger P.P., van Staveren W.C. Cancer stem cells: a reality, a myth, a fuzzy concept or a misnomer? an analysis. Carcinogenesis 2010, 31:149-158.
16. Driessens G., Beck B., Caauwe A., Simons B.D., Blanpain C. Defining the mode of tumour growth by clonal analysis. Nature 2012, 488:527-530.
17. Chen J., Li Y., Yu T.S., McKay R.M., Burns D.K., Kernie S.G., et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 2012, 488:522-526.
18. Schepers A.G., Snippert H.J., Stange D.E., van den Born M., van Es J.H., van de Wetering M., et al. Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. Science 2012, 337:730-735.
19. Eramo A., Ricci-Vitiani L., Zeuner A., Pallini R., Lotti F., Sette G., et al. Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ. 2006, 13:1238-1241.
20. Yu F., Yao H., Zhu P., Zhang X., Pan Q., Gong C., et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007, 131:1109-1123.
21. Dylla S.J., Beviglia L., Park I.K., Chartier C., Raval J., Ngan L., et al. Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PloS One 2008, 3:e2428.
22. Liu Y.P., Yang C.J., Huang M.S., Yeh C.T., Wu A.T., Lee Y.C., et al. Cisplatin selects for multidrug-resistant CD133+ cells in lung adenocarcinoma by activating Notch signaling. Cancer Res. 2013, 73:406-416.
23. Diehn M., Cho R.W., Lobo N.A., Kalisky T., Dorie M.J., Kulp A.N., et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009, 458:780-783.
24. Dean M., Fojo T., Bates S. Tumour stem cells and drug resistance. Nat. Rev. Cancer 2005, 5:275-284.
25. Vinogradov S., Wei X. Cancer stem cells and drug resistance: the potential of nanomedicine. Nanomedicine (Lond) 2012, 7:597-615.
26. Ma S., Lee T.K., Zheng B.J., Chan K.W., Guan X.Y. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 2008, 27:1749-1758.
27. Yu Y., Ramena G., Elble R.C. The role of cancer stem cells in relapse of solid tumors. Front. Biosci. (Elite Ed.) 2012, 4:1528-1541.
28. Li Y., Rogoff H.A., Keates S., Gao Y., Murikipudi S., Mikule K., et al. Suppression of cancer relapse and metastasis by inhibiting cancer stemness. Proc. Natl. Acad. Sci. U. S. A. 2015, 112:1839-1844.
29. Flemming A. Cancer stem cells: targeting the root of cancer relapse. Nat. Rev. Drug Discov. 2015, 14:165.
30. Beck B., Blanpain C. Unravelling cancer stem cell potential. Nat. Rev. Cancer 2013, 13:727-738.
31. Chen K., Huang Y.H., Chen J.L. Understanding and targeting cancer stem cells: therapeutic implications and challenges. Acta Pharmacol. Sin. 2013, 34:732-740.
32. Gupta P.B., Onder T.T., Jiang G., Tao K., Kuperwasser C., Weinberg R.A., et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009, 138:645-659.
33. Li Y., Zhang T. Targeting cancer stem cells by curcumin and clinical applications. Cancer Lett. 2014, 346:197-205.
34. Sachlos E., Risueno R.M., Laronde S., Shapovalova Z., Lee J.H., Russell J., et al. Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. Cell 2012, 149:1284-1297.
35. Li Y., Zhang T., Korkaya H., Liu S., Lee H.F., Newman B., et al. Sulforaphane, a dietary component of broccoli/broccoli sprouts, inhibits breast cancer stem cells. Clin. Cancer Res. 2010, 16:2580-2590.
36. Liu C., Kelnar K., Liu B., Chen X., Calhoun-Davis T., Li H., et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat. Med. 2011, 17:211-215.
37. Ma S., Tang K.H., Chan Y.P., Lee T.K., Kwan P.S., Castilho A., et al. miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Cell Stem Cell 2010, 7:694-707.
38. Chen Z.G. Small-molecule delivery by nanoparticles for anticancer therapy. Trends Mol. Med. 2010, 16:594-602.
39. Davis M.E., Chen Z.G., Shin D.M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov. 2008, 7:771-782.
40. Rink J.S., Plebanek M.P., Tripathy S., Thaxton C.S. Update on current and potential nanoparticle cancer therapies. Curr. Opin. Oncol. 2013, 25:646-651.
41. Sun T., Zhang Y.S., Pang B., Hyun D.C., Yang M., Xia Y. Engineered nanoparticles for drug delivery in cancer therapy. Angew. Chem. Int. Ed. 2014, 53:12320-12364.
42. Barenholz Y. Doxil(R)-the first FDA-approved nano-drug: lessons learned. J. Control. Releas. 2012, 160:117-134.
43. Gordon A.N., Fleagle J.T., Guthrie D., Parkin D.E., Gore M.E., Lacave A.J. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol. 2001, 19:3312-3322.
44. Gordon A.N., Tonda M., Sun S., Rackoff W. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol. Oncol. 2004, 95:1-8.
45. Zhao Y., Alakhova D.Y., Kabanov A.V. Can nanomedicines kill cancer stem cells?. Adv. Drug Deliv. Rev. 2013, 65:1763-1783.
46. Lim K.J., Bisht S., Bar E.E., Maitra A., Eberhart C.G. A polymeric nanoparticle formulation of curcumin inhibits growth, clonogenicity and stem-like fraction in malignant brain tumors. Cancer Biol. Ther. 2011, 11:464-473.
47. Sun R., Liu Y., Li S.Y., Shen S., Du X.J., Xu C.F., et al. Co-delivery of all-trans-retinoic acid and doxorubicin for cancer therapy with synergistic inhibition of cancer stem cells. Biomaterials 2015, 37:405-414.
48. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
49. Nguyen L.V., Vanner R., Dirks P., Eaves C.J. Cancer stem cells: an evolving concept. Nat. Rev. Cancer 2012, 12:133-143.
50. Plaks V., Kong N., Werb Z. The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells?. Cell Stem Cell 2015, 16:225-238.
51. Medema J.P. Cancer stem cells: the challenges ahead. Nat. Cell Biol. 2013, 15:338-344.
52. Oates J.E., Grey B.R., Addla S.K., Samuel J.D., Hart C.A., Ramani V.A., et al. Hoechst 33342 side population identification is a conserved and unified mechanism in urological cancers. Stem Cells Dev. 2009, 18:1515-1522.
53. Bjerkvig R., Tysnes B.B., Aboody K.S., Najbauer J., Terzis A.J. Opinion: the origin of the cancer stem cell: current controversies and new insights. Nat. Rev. Cancer 2005, 5:899-904.
54. Bu Y., Cao D. The origin of cancer stem cells. Front. Biosci. Sch. Ed. 2012, 4:819-830.
55. Mani S.A., Guo W., Liao M.J., Eaton E.N., Ayyanan A., Zhou A.Y., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715.
56. Bao S., Wu Q., McLendon R.E., Hao Y., Shi Q., Hjelmeland A.B., et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760.
57. Woodward W.A., Chen M.S., Behbod F., Alfaro M.P., Buchholz T.A., Rosen J.M. WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:618-623.
58. Gottesman M.M., Fojo T., Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2002, 2:48-58.
59. Britton K.M., Eyre R., Harvey I.J., Stemke-Hale K., Browell D., Lennard T.W., et al. Breast cancer, side population cells and ABCG2 expression. Cancer Lett. 2012, 323:97-105.
60. Goodell M.A., Brose K., Paradis G., Conner A.S., Mulligan R.C. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J. Exp. Med. 1996, 183:1797-1806.
61. Ho M.M., Ng A.V., Lam S., Hung J.Y. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res. 2007, 67:4827-4833.
62. Hirschmann-Jax C., Foster A.E., Wulf G.G., Nuchtern J.G., Jax T.W., Gobel U., et al. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:14228-14233.
63. Rabindran S.K., Ross D.D., Doyle L.A., Yang W., Greenberger L.M. Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res. 2000, 60:47-50.
64. Woehlecke H., Osada H., Herrmann A., Lage H. Reversal of breast cancer resistance protein-mediated drug resistance by tryprostatin A. Int. J. Cancer 2003, 107:721-728.
65. Nobili S., Landini I., Giglioni B., Mini E. Pharmacological strategies for overcoming multidrug resistance. Curr. Drug Targets 2006, 7:861-879.
66. Angelastro J.M., Lame M.W. Overexpression of CD133 promotes drug resistance in C6 glioma cells. Mol. Cancer Res. 2010, 8:1105-1115.
67. Frank N.Y., Pendse S.S., Lapchak P.H., Margaryan A., Shlain D., Doeing C., et al. Regulation of progenitor cell fusion by ABCB5 P-glycoprotein, a novel human ATP-binding cassette transporter. J. Biol. Chem. 2003, 278:47156-47165.
68. Frank N.Y., Margaryan A., Huang Y., Schatton T., Waaga-Gasser A.M., Gasser M., et al. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res. 2005, 65:4320-4333.
69. Thomas H., Coley H.M. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control. 2003, 10:159-165.
70. Takahashi-Yanaga F., Kahn M. Targeting Wnt signaling: can we safely eradicate cancer stem cells?. Clin. Cancer Res. 2010, 16:3153-3162.
71. Merchant A.A., Matsui W. Targeting Hedgehog-a cancer stem cell pathway. Clin. Cancer Res. 2010, 16:3130-3140.
72. Pannuti A., Foreman K., Rizzo P., Osipo C., Golde T., Osborne B., et al. Targeting Notch to target cancer stem cells. Clin. Cancer Res. 2010, 16:3141-3152.
73. Takebe N., Harris P.J., Warren R.Q., Ivy S.P. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat. Rev. Clin. Oncol. 2011, 8:97-106.
74. Campbell C., Risueno R.M., Salati S., Guezguez B., Bhatia M. Signal control of hematopoietic stem cell fate: Wnt, Notch, and Hedgehog as the usual suspects. Curr. Opin. Hematol. 2008, 15:319-325.
75. McGowan P.M., Simedrea C., Ribot E.J., Foster P.J., Palmieri D., Steeg P.S., et al. Notch1 inhibition alters the CD44hi/CD24lo population and reduces the formation of brain metastases from breast cancer. Mol. Cancer Res. 2011, 9:834-844.
76. He B., Reguart N., You L., Mazieres J., Xu Z., Lee A.Y., et al. Blockade of Wnt-1 signaling induces apoptosis in human colorectal cancer cells containing downstream mutations. Oncogene 2005, 24:3054-3058.
77. Feldmann G., Habbe N., Dhara S., Bisht S., Alvarez H., Fendrich V., et al. Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer. Gut 2008, 57:1420-1430.
78. Karhadkar S.S., Bova G.S., Abdallah N., Dhara S., Gardner D., Maitra A., et al. Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature 2004, 431:707-712.
79. Brown J.M., Attardi L.D. The role of apoptosis in cancer development and treatment response. Nat. Rev. Cancer 2005, 5:231-237.
80. Domen J., Cheshier S.H., Weissman I.L. The role of apoptosis in the regulation of hematopoietic stem cells: overexpression of Bcl-2 increases both their number and repopulation potential. J. Exp. Med. 2000, 191:253-264.
81. Goff D.J., Court Recart A., Sadarangani A., Chun H.J., Barrett C.L., Krajewska M., et al. A pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition. Cell Stem Cell 2013, 12:316-328.
82. Lang J.Y., Hsu J.L., Meric-Bernstam F., Chang C.J., Wang Q., Bao Y., et al. BikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatment. Cancer Cell 2011, 20:341-356.
83. Baud V., Karin M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat. Rev. Drug Discov. 2009, 8:33-40.
84. Garner J.M., Fan M., Yang C.H., Du Z., Sims M., Davidoff A.M., et al. Constitutive activation of signal transducer and activator of transcription 3 (STAT3) and nuclear factor kappaB signaling in glioblastoma cancer stem cells regulates the Notch pathway. J. Biol. Chem. 2013, 288:26167-26176.
85. Chung S.S., Vadgama J.V. Curcumin and epigallocatechin gallate inhibit the cancer stem cell phenotype via down-regulation of STAT3-NFkappaB signaling. Anticancer Res. 2015, 35:39-46.
86. Todaro M., Alea M.P., Di Stefano A.B., Cammareri P., Vermeulen L., Iovino F., et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 2007, 1:389-402.
87. Ginestier C., Liu S., Diebel M.E., Korkaya H., Luo M., Brown M., et al. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J. Clin. Invest. 2010, 120:485-497.
88. Oskarsson T., Batlle E., Massague J. Metastatic stem cells: sources, niches, and vital pathways. Cell Stem Cell 2014, 14:306-321.
89. Ye J., Wu D., Wu P., Chen Z., Huang J. The cancer stem cell niche: cross talk between cancer stem cells and their microenvironment. Tumor Biol. 2014, 35:3945-3951.
90. Beck B., Driessens G., Goossens S., Youssef K.K., Kuchnio A., Caauwe A., et al. A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours. Nature 2011, 478:399-403.
91. Bao S., Wu Q., Sathornsumetee S., Hao Y., Li Z., Hjelmeland A.B., et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res. 2006, 66:7843-7848.
92. Vermeulen L., De Sousa E.M.F., van der Heijden M., Cameron K., de Jong J.H., Borovski T., et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat. Cell Biol. 2010, 12:468-476.
93. Li Z., Bao S., Wu Q., Wang H., Eyler C., Sathornsumetee S., et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 2009, 15:501-513.
94. Raaijmakers M.H., Mukherjee S., Guo S., Zhang S., Kobayashi T., Schoonmaker J.A., et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 2010, 464:852-857.
95. Jin L., Hope K.J., Zhai Q., Smadja-Joffe F., Dick J.E. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat. Med. 2006, 12:1167-1174.
96. Jin L., Lee E.M., Ramshaw H.S., Busfield S.J., Peoppl A.G., Wilkinson L., et al. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell 2009, 5:31-42.
97. Kikushige Y., Shima T., Takayanagi S., Urata S., Miyamoto T., Iwasaki H., et al. TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell 2010, 7:708-717.
98. Haraguchi N., Ishii H., Mimori K., Tanaka F., Ohkuma M., Kim H.M., et al. CD13 is a therapeutic target in human liver cancer stem cells. J. Clin. Invest. 2010, 120:3326-3339.
99. Bertolini G., Roz L., Perego P., Tortoreto M., Fontanella E., Gatti L., et al. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:16281-16286.
100. Rountree C.B., Ding W., He L., Stiles B. Expansion of CD133-expressing liver cancer stem cells in liver-specific phosphatase and tensin homolog deleted on chromosome 10-deleted mice. Stem Cells 2009, 27:290-299.
101. Brescia P., Ortensi B., Fornasari L., Levi D., Broggi G., Pelicci G. CD133 is essential for glioblastoma stem cell maintenance. Stem Cells 2013, 31:857-869.
102. Choi A.M., Ryter S.W., Levine B. Autophagy in human health and disease. N. Engl. J. Med. 2013, 368:651-662.
103. Sui X., Chen R., Wang Z., Huang Z., Kong N., Zhang M., et al. Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment. Cell Death Dis. 2013, 4:e838.
104. Yousefi S., Simon H.U. Autophagy in cancer and chemotherapy. Results Probl. Cell Differ. 2009, 49:183-190.
105. Zhuang W., Li B., Long L., Chen L., Huang Q., Liang Z. Induction of autophagy promotes differentiation of glioma-initiating cells and their radiosensitivity. Int. J. Cancer 2011, 129:2720-2731.
106. Cufi S., Vazquez-Martin A., Oliveras-Ferraros C., Martin-Castillo B., Vellon L., Menendez J.A. Autophagy positively regulates the CD44(+) CD24(-/low) breast cancer stem-like phenotype. Cell Cycle 2011, 10:3871-3885.
107. Maycotte P., Jones K.L., Goodall M.L., Thorburn J., Thorburn A. Autophagy supports breast cancer stem cell maintenance by regulating IL6 secretion. Mol. Cancer Res. 2015, 13:651-658.
108. Zhou J., Wulfkuhle J., Zhang H., Gu P., Yang Y., Deng J., et al. Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:16158-16163.
109. Hirsch H.A., Iliopoulos D., Tsichlis P.N., Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 2009, 69:7507-7511.
110. Balic A., Sorensen M.D., Trabulo S.M., Sainz B., Cioffi M., Vieira C.R., et al. Chloroquine targets pancreatic cancer stem cells via inhibition of CXCR4 and hedgehog signaling. Mol. Cancer Ther. 2014, 13:1758-1771.
111. Ward P.S., Thompson C.B. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 2012, 21:297-308.
112. Menendez J.A., Joven J., Cufi S., Corominas-Faja B., Oliveras-Ferraros C., Cuyas E., et al. The Warburg effect version 2.0: metabolic reprogramming of cancer stem cells. Cell Cycle 2013, 12:1166-1179.
113. Flavahan W.A., Wu Q., Hitomi M., Rahim N., Kim Y., Sloan A.E., et al. Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake. Nat. Neurosci. 2013, 16:1373-1382.
114. Ginestier C., Monville F., Wicinski J., Cabaud O., Cervera N., Josselin E., et al. Mevalonate metabolism regulates Basal breast cancer stem cells and is a potential therapeutic target. Stem Cells 2012, 30:1327-1337.
115. Hirsch H.A., Iliopoulos D., Struhl K. Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:972-977.
116. Wurth R., Pattarozzi A., Gatti M., Bajetto A., Corsaro A., Parodi A., et al. Metformin selectively affects human glioblastoma tumor-initiating cell viability: a role for metformin-induced inhibition of Akt. Cell Cycle 2013, 12:145-156.
117. Gao Z., Zhang L., Sun Y. Nanotechnology applied to overcome tumor drug resistance. J. Control. Release 2012, 162:45-55.
118. Xia P. Surface markers of cancer stem cells in solid tumors. Curr. Stem Cell Res. Ther. 2014, 9:102-111.
119. Mohyeldin A., Garzon-Muvdi T., Quinones-Hinojosa A. Oxygen in stem cell biology: a critical component of the stem cell niche. Cell Stem Cell 2010, 7:150-161.
120. Markman J.L., Rekechenetskiy A., Holler E., Ljubimova J.Y. Nanomedicine therapeutic approaches to overcome cancer drug resistance. Adv. Drug Deliv. Rev. 2013, 65:1866-1879.
121. Livney Y.D., Assaraf Y.G. Rationally designed nanovehicles to overcome cancer chemoresistance. Adv. Drug Deliv. Rev. 2013, 65:1716-1730.
122. Hu Y., Fu L. Targeting cancer stem cells: a new therapy to cure cancer patients. Am. J. Cancer Res. 2012, 2:340-356.
123. Yao H.J., Zhang Y.G., Sun L., Liu Y. The effect of hyaluronic acid functionalized carbon nanotubes loaded with salinomycin on gastric cancer stem cells. Biomaterials 2014, 35:9208-9223.
124. Wang K., Zhang T., Liu L., Wang X., Wu P., Chen Z., et al. Novel micelle formulation of curcumin for enhancing antitumor activity and inhibiting colorectal cancer stem cells. Int. J. Nanomed. 2012, 7:4487-4497.
125. Zhou Y., Yang J., Kopecek J. Selective inhibitory effect of HPMA copolymer-cyclopamine conjugate on prostate cancer stem cells. Biomaterials 2012, 33:1863-1872.
126. Sun T.M., Wang Y.C., Wang F., Du J.Z., Mao C.Q., Sun C.Y., et al. Cancer stem cell therapy using doxorubicin conjugated to gold nanoparticles via hydrazone bonds. Biomaterials 2014, 35:836-845.
127. Wang K., Liu L., Zhang T., Zhu Y.L., Qiu F., Wu X.G., et al. Oxaliplatin-incorporated micelles eliminate both cancer stem-like and bulk cell populations in colorectal cancer. Int. J. Nanomed. 2011, 6:3207-3218.
128. Zhao P., Dong S., Bhattacharyya J., Chen M. iTEP nanoparticle-delivered salinomycin displays an enhanced toxicity to cancer stem cells in orthotopic breast tumors. Mol. Pharm. 2014, 11:2703-2712.
129. Wei X., Senanayake T.H., Warren G., Vinogradov S.V. Hyaluronic acid-based nanogel-drug conjugates with enhanced anticancer activity designed for the targeting of CD44-positive and drug-resistant tumors. Bioconjugate Chem. 2013, 24:658-668.
130. Krishnamurthy S., Ng V.W., Gao S., Tan M.H., Yang Y.Y. Phenformin-loaded polymeric micelles for targeting both cancer cells and cancer stem cells in vitro and in vivo. Biomaterials 2014, 35:9177-9186.
131. Shen S., Du X.J., Liu J., Sun R., Zhu Y.H., Wang J. Delivery of bortezomib with nanoparticles for basal-like triple-negative breast cancer therapy. J. Control. Release 2015, 208:14-24.
132. Wang X., Low X.C., Hou W., Abdullah L.N., Toh T.B., Mohd Abdul Rashid M., et al. Epirubicin-adsorbed nanodiamonds kill chemoresistant hepatic cancer stem cells. ACS Nano 2014, 8:12151-12166.
133. Kalota A., Shetzline S.E., Gewirtz A.M. Progress in the development of nucleic acid therapeutics for cancer. Cancer Biol. Ther. 2004, 3:4-12.
134. Pai S.I., Lin Y.Y., Macaes B., Meneshian A., Hung C.F., Wu T.C. Prospects of RNA interference therapy for cancer. Gene Ther. 2006, 13:464-477.
135. Hu T., Liu S., Breiter D.R., Wang F., Tang Y., Sun S. Octamer 4 small interfering RNA results in cancer stem cell-like cell apoptosis. Cancer Res. 2008, 68:6533-6540.
136. Muthiah M., Park I.K., Cho C.S. Nanoparticle-mediated delivery of therapeutic genes: focus on miRNA therapeutics. Expert Opin. Drug Deliv. 2013, 10:1259-1273.
137. Wu Y., Crawford M., Yu B., Mao Y., Nana-Sinkam S.P., Lee L.J. MicroRNA delivery by cationic lipoplexes for lung cancer therapy. Mol. Pharm. 2011, 8:1381-1389.
138. Yang Y.P., Chien Y., Chiou G.Y., Cherng J.Y., Wang M.L., Lo W.L., et al. Inhibition of cancer stem cell-like properties and reduced chemoradioresistance of glioblastoma using microRNA145 with cationic polyurethane-short branch PEI. Biomaterials 2012, 33:1462-1476.
139. Piao L., Zhang M., Datta J., Xie X., Su T., Li H., et al. Lipid-based nanoparticle delivery of Pre-miR-107 inhibits the tumorigenicity of head and neck squamous cell carcinoma. Mol. Ther. 2012, 20:1261-1269.
140. Shi S., Han L., Gong T., Zhang Z., Sun X. Systemic delivery of microRNA-34a for cancer stem cell therapy. Angew. Chem. Int. Ed. 2013, 52:3901-3905.
141. Williford J.M., Wu J., Ren Y., Archang M.M., Leong K.W., Mao H.Q. Recent advances in nanoparticle-mediated siRNA delivery. Annu. Rev. Biomed. Eng. 2014, 16:347-370.
142. Andey T., Marepally S., Patel A., Jackson T., Sarkar S., O'Connell M., et al. Cationic lipid guided short-hairpin RNA interference of annexin A2 attenuates tumor growth and metastasis in a mouse lung cancer stem cell model. J. Control. Release 2014, 184:67-78.
143. Xu C.F., Liu Y., Shen S., Zhu Y.H., Wang J. Targeting glucose uptake with siRNA-based nanomedicine for cancer therapy. Biomaterials 2015, 51:1-11.
144. Liu C., Zhao G., Liu J., Ma N., Chivukula P., Perelman L., et al. Novel biodegradable lipid nano complex for siRNA delivery significantly improving the chemosensitivity of human colon cancer stem cells to paclitaxel. J. Control. Release 2009, 140:277-283.
145. Chiou G.Y., Cherng J.Y., Hsu H.S., Wang M.L., Tsai C.M., Lu K.H., et al. Cationic polyurethanes-short branch PEI-mediated delivery of miR145 inhibited epithelial-mesenchymal transdifferentiation and cancer stem-like properties and in lung adenocarcinoma. J. Control. Release 2012, 159:240-250.
146. Cui F.B., Liu Q., Li R.T., Shen J., Wu P.Y., Yu L.X., et al. Enhancement of radiotherapy efficacy by miR-200c-loaded gelatinase-stimuli PEG-Pep-PCL nanoparticles in gastric cancer cells. Int. J. Nanomed 2014, 9:2345-2358.
147. Lo W.L., Chien Y., Chiou G.Y., Tseng L.M., Hsu H.S., Chang Y.L., et al. Nuclear localization signal-enhanced RNA interference of EZH2 and Oct4 in the eradication of head and neck squamous cell carcinoma-derived cancer stem cells. Biomaterials 2012, 33:3693-3709.
148. Gul-Uludag H., Valencia-Serna J., Kucharski C., Marquez-Curtis L.A., Jiang X., Larratt L., et al. Polymeric nanoparticle-mediated silencing of CD44 receptor in CD34+ acute myeloid leukemia cells. Leuk. Res. 2014, 38:1299-1308.
149. Zhang Y., Zhang H., Wang X., Wang J., Zhang X., Zhang Q. The eradication of breast cancer and cancer stem cells using octreotide modified paclitaxel active targeting micelles and salinomycin passive targeting micelles. Biomaterials 2012, 33:679-691.
150. Zhou Y., Yang J., Rhim J.S., Kopecek J. HPMA copolymer-based combination therapy toxic to both prostate cancer stem/progenitor cells and differentiated cells induces durable anti-tumor effects. J. Control. Release 2013, 172:946-953.
151. Ke X.Y., Lin Ng V.W., Gao S.J., Tong Y.W., Hedrick J.L., Yang Y.Y. Co-delivery of thioridazine and doxorubicin using polymeric micelles for targeting both cancer cells and cancer stem cells. Biomaterials 2014, 35:1096-1108.
152. Shimono Y., Zabala M., Cho R.W., Lobo N., Dalerba P., Qian D., et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 2009, 138:592-603.
153. Liu Q., Li R.T., Qian H.Q., Wei J., Xie L., Shen J., et al. Targeted delivery of miR-200c/DOC to inhibit cancer stem cells and cancer cells by the gelatinases-stimuli nanoparticles. Biomaterials 2013, 34:7191-7203.
154. Yang C., Xiong F., Wang J., Dou J., Chen J., Chen D., et al. Anti-ABCG2 monoclonal antibody in combination with paclitaxel nanoparticles against cancer stem-like cell activity in multiple myeloma. Nanomedicine (Lond) 2014, 9:45-60.
155. Li S.Y., Sun R., Wang H.X., Shen S., Liu Y., Du X.J., et al. Combination therapy with epigenetic-targeted and chemotherapeutic drugs delivered by nanoparticles to enhance the chemotherapy response and overcome resistance by breast cancer stem cells. J. Control. Release 2015, 205:7-14.
156. Wang D., Huang J., Wang X., Yu Y., Zhang H., Chen Y., et al. The eradication of breast cancer cells and stem cells by 8-hydroxyquinoline-loaded hyaluronan modified mesoporous silica nanoparticle-supported lipid bilayers containing docetaxel. Biomaterials 2013, 34:7662-7673.
157. Liu Y., Lu W.L., Guo J., Du J., Li T., Wu J.W., et al. A potential target associated with both cancer and cancer stem cells: a combination therapy for eradication of breast cancer using vinorelbine stealthy liposomes plus parthenolide stealthy liposomes. J. Control. Release 2008, 129:18-25.
158. Kim S.S., Rait A., Kim E., Pirollo K.F., Nishida M., Farkas N., et al. A nanoparticle carrying the p53 gene targets tumors including cancer stem cells, sensitizes glioblastoma to chemotherapy and improves survival. ACS Nano 2014, 8:5494-5514.
159. Swaminathan S.K., Roger E., Toti U., Niu L., Ohlfest J.R., Panyam J. CD133-targeted paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer. J. Control. Release 2013, 171:280-287.
160. Ganesh S., Iyer A.K., Morrissey D.V., Amiji M.M. Hyaluronic acid based self-assembling nanosystems for CD44 target mediated siRNA delivery to solid tumors. Biomaterials 2013, 34:3489-3502.
161. Rao W., Wang H., Han J., Zhao S., Dumbleton J., Agarwal P., et al. Chitosan-decorated doxorubicin-encapsulated nanoparticle targets and eliminates tumor reinitiating cancer stem-like cells. ACS Nano 2015, 9:5725-5740.
162. Wang L., Su W., Liu Z., Zhou M., Chen S., Chen Y., et al. CD44 antibody-targeted liposomal nanoparticles for molecular imaging and therapy of hepatocellular carcinoma. Biomaterials 2012, 33:5107-5114.
163. Kim S.S., Rait A., Rubab F., Rao A.K., Kiritsy M.C., Pirollo K.F., et al. The clinical potential of targeted nanomedicine: delivering to cancer stem-like cells. Mol. Ther. 2014, 22:278-291.
164. Kaluzova M., Bouras A., Machaidze R., Hadjipanayis C.G. Targeted therapy of glioblastoma stem-like cells and tumor non-stem cells using cetuximab-conjugated iron-oxide nanoparticles. Oncotarget 2015, 6:8788-8806.
165. Cheng Z., Al Zaki A., Hui J.Z., Muzykantov V.R., Tsourkas A. Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science 2012, 338:903-910.
166. McNeeley K.M., Annapragada A., Bellamkonda R.V. Decreased circulation time offsets increased efficacy of PEGylated nanocarriers targeting folate receptors of glioma. Nanotechnology 2007, 18:385101-385112.
167. Lee H., Fonge H., Hoang B., Reilly R.M., Allen C. The effects of particle size and molecular targeting on the intratumoral and subcellular distribution of polymeric nanoparticles. Mol. Pharm. 2010, 7:1195-1208.
168. Keith B., Simon M.C. Hypoxia-inducible factors, stem cells, and cancer. Cell 2007, 129:465-472.
169. Tai W., Mahato R., Cheng K. The role of HER2 in cancer therapy and targeted drug delivery. J. Control. Release 2010, 146:264-275.
170. Daniels T.R., Bernabeu E., Rodriguez J.A., Patel S., Kozman M., Chiappetta D.A., et al. The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim. Biophys. Acta 2012, 1820:291-317.
171. Knop K., Hoogenboom R., Fischer D., Schubert U.S. Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew. Chem. Int. Ed. 2010, 49:6288-6308.
172. Mishra S., Webster P., Davis M.E. PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles. Eur. J. Cell Biol. 2004, 83:97-111.
173. Huang S., Shao K., Liu Y., Kuang Y., Li J., An S., et al. Tumor-targeting and microenvironment-responsive smart nanoparticles for combination therapy of antiangiogenesis and apoptosis. ACS Nano 2013, 7:2860-2871.
174. Mura S., Nicolas J., Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat. Mater 2013, 12:991-1003.
175. Kale A.A., Torchilin V.P. Environment-responsive multifunctional liposomes. Methods Mol. Biol. 2010, 605:213-242.
176. Kessenbrock K., Plaks V., Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010, 141:52-67.
177. Wang H.X., Yang X.Z., Sun C.Y., Mao C.Q., Zhu Y.H., Wang J. Matrix metalloproteinase 2-responsive micelle for siRNA delivery. Biomaterials 2014, 35:7622-7634.
178. Charles N., Ozawa T., Squatrito M., Bleau A.M., Brennan C.W., Hambardzumyan D., et al. Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells. Cell Stem Cell 2010, 6:141-152.
179. Liu S., Cong Y., Wang D., Sun Y., Deng L., Liu Y., et al. Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts. Stem Cell Rep. 2014, 2:78-91.
180. Kim B., Han G., Toley B.J., Kim C.K., Rotello V.M., Forbes N.S. Tuning payload delivery in tumour cylindroids using gold nanoparticles. Nat. Nanotechnol. 2010, 5:465-472.
181. Jokerst J.V., Lobovkina T., Zare R.N., Gambhir S.S. Nanoparticle PEGylation for imaging and therapy. Nanomedicine (Lond) 2011, 6:715-728.
182. Cabral H., Matsumoto Y., Mizuno K., Chen Q., Murakami M., Kimura M., et al. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat. Nanotechnol. 2011, 6:815-823.
183. Ruoslahti E. Peptides as targeting elements and tissue penetration devices for nanoparticles. Adv. Mater 2012, 24:3747-3756.
184. Sun Q., Sun X., Ma X., Zhou Z., Jin E., Zhang B., et al. Integration of nanoassembly functions for an effective delivery cascade for cancer drugs. Adv. Mater 2014, 26:7615-7621.
185. Castanotto D., Rossi J.J. The promises and pitfalls of RNA-interference-based therapeutics. Nature 2009, 457:426-433.
186. Mittal V. Improving the efficiency of RNA interference in mammals. Nat. Rev. Genet. 2004, 5:355-365.
187. Jackson A.L., Linsley P.S. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat. Rev. Drug Discov. 2010, 9:57-67.
188. Smith J., Grizot S., Arnould S., Duclert A., Epinat J.C., Chames P., et al. A combinatorial approach to create artificial homing endonucleases cleaving chosen sequences. Nucleic Acids Res. 2006, 34:e149.
189. Boissel S., Jarjour J., Astrakhan A., Adey A., Gouble A., Duchateau P., et al. megaTALs: a rare-cleaving nuclease architecture for therapeutic genome engineering. Nucleic Acids Res. 2014, 42:2591-2601.
190. Wolfe S.A., Nekludova L., Pabo C.O. DNA recognition by Cys2His2 zinc finger proteins. Annu. Rev. Biophys. Biomol. Struct. 2000, 29:183-212.
191. Bibikova M., Beumer K., Trautman J.K., Carroll D. Enhancing gene targeting with designed zinc finger nucleases. Science 2003, 300:764.
192. Christian M., Cermak T., Doyle E.L., Schmidt C., Zhang F., Hummel A., et al. Targeting DNA double-strand breaks with TAL effector nucleases. Genetics 2010, 186:757-761.
193. Miller J.C., Tan S., Qiao G., Barlow K.A., Wang J., Xia D.F., et al. A TALE nuclease architecture for efficient genome editing. Nat. Biotechnol. 2011, 29:143-148.
194. Cong L., Ran F.A., Cox D., Lin S., Barretto R., Habib N., et al. Multiplex genome engineering using CRISPR/Cas systems. Science 2013, 339:819-823.
195. Ran F.A., Hsu P.D., Wright J., Agarwala V., Scott D.A., Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 2013, 8:2281-2308.
196. Cox D.B., Platt R.J., Zhang F. Therapeutic genome editing: prospects and challenges. Nat. Med. 2015, 21:121-131.
197. Boettcher M., McManus M.T. Choosing the right tool for the job: RNAi, TALEN, or CRISPR. Mol. Cell 2015, 58:575-585.
198. Shalem O., Sanjana N.E., Hartenian E., Shi X., Scott D.A., Mikkelsen T.S., et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 2014, 343:84-87.
199. Qi L.S., Larson M.H., Gilbert L.A., Doudna J.A., Weissman J.S., Arkin A.P., et al. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell 2013, 152:1173-1183.
200. Aida T., Chiyo K., Usami T., Ishikubo H., Imahashi R., Wada Y., et al. Cloning-free CRISPR/Cas system facilitates functional cassette knock-in in mice. Genome Biol. 2015, 16:87.
201. Platt R.J., Chen S., Zhou Y., Yim M.J., Swiech L., Kempton H.R., et al. CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell 2014, 159:440-455.
202. Zhang L., Sun H., Zhao F., Lu P., Ge C., Li H., et al. BMP4 administration induces differentiation of CD133+ hepatic cancer stem cells, blocking their contributions to hepatocellular carcinoma. Cancer Res. 2012, 72:4276-4285.
203. Wu Z., Yang H., Colosi P. Effect of genome size on AAV vector packaging. Mol. Ther. 2010, 18:80-86.
204. Bessis N., GarciaCozar F.J., Boissier M.C. Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene Ther. 2004, 11(Suppl. 1):S10-S17.
205. Zuris J.A., Thompson D.B., Shu Y., Guilinger J.P., Bessen J.L., Hu J.H., et al. Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo. Nat. Biotechnol. 2015, 33:73-80.
206. Korkaya H., Liu S., Wicha M.S. Breast cancer stem cells, cytokine networks, and the tumor microenvironment. J. Clin. Invest 2011, 121:3804-3809.
207. Pan Q., Li Q., Liu S., Ning N., Zhang X., Xu Y., et al. Concise reviews: targeting cancer stem cells using immunologic approaches. Stem Cells 2015, 33:2085-2092.
208. Lu H., Clauser K.R., Tam W.L., Frose J., Ye X., Eaton E.N., et al. A breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages. Nat. Cell Biol. 2014, 16:1105-1117.
209. Wang B., Wang Q., Wang Z., Jiang J., Yu S.C., Ping Y.F., et al. Metastatic consequences of immune escape from NK cell cytotoxicity by human breast cancer stem cells. Cancer Res. 2014, 74:5746-5757.
210. Visus C., Wang Y., Lozano-Leon A., Ferris R.L., Silver S., Szczepanski M.J., et al. Targeting ALDH(bright) human carcinoma-initiating cells with ALDH1A1-specific CD8(+) T cells. Clin. Cancer Res. 2011, 17:6174-6184.
211. Ning N., Pan Q., Zheng F., Teitz-Tennenbaum S., Egenti M., Yet J., et al. Cancer stem cell vaccination confers significant antitumor immunity. Cancer Res. 2012, 72:1853-1864.
212. Toda M. Glioma stem cells and immunotherapy for the treatment of malignant gliomas. ISRN Oncol. 2013, 2013:673793.
213. Duarte S., Momier D., Baque P., Casanova V., Loubat A., Samson M., et al. Preventive cancer stem cell-based vaccination reduces liver metastasis development in a rat colon carcinoma syngeneic model. Stem Cells 2013, 31:423-432.
214. Goldberg M.S. Immunoengineering: how nanotechnology can enhance cancer immunotherapy. Cell 2015, 161:201-204.
215. Park Y.M., Lee S.J., Kim Y.S., Lee M.H., Cha G.S., Jung I.D., et al. Nanoparticle-based vaccine delivery for cancer immunotherapy. Immune Netw. 2013, 13:177-183.
216. Leuschner F., Dutta P., Gorbatov R., Novobrantseva T.I., Donahoe J.S., Courties G., et al. Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat. Biotechnol. 2011, 29:1005-1010.
217. Zhu S., Niu M., O'Mary H., Cui Z. Targeting of tumor-associated macrophages made possible by PEG-sheddable, mannose-modified Nan particles. Mol. Pharm. 2013, 10:3525-3530.
218. Cruz L.J., Tacken P.J., Rueda F., Domingo J.C., Albericio F., Figdor C.G. Targeting nanoparticles to dendritic cells for immunotherapy. Methods Enzymol. 2012, 509:143-163.